Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

Signs of neurological damage over time may not be needed for a diagnosis of MS in patients who strongly meet other criteria, ...

ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. Read more about ZLAB stock here.

Rabies is one of the oldest communicable diseases known to humans and is almost always fatal, with very few cases of ...